1. Home
  2. CRVS vs INMD Comparison

CRVS vs INMD Comparison

Compare CRVS & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

N/A

Current Price

$10.60

Market Cap

843.7M

Sector

Health Care

ML Signal

N/A

Logo InMode Ltd.

INMD

InMode Ltd.

N/A

Current Price

$13.37

Market Cap

805.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CRVS
INMD
Founded
2014
2008
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
843.7M
805.0M
IPO Year
2016
2018

Fundamental Metrics

Financial Performance
Metric
CRVS
INMD
Price
$10.60
$13.37
Analyst Decision
Strong Buy
Hold
Analyst Count
7
5
Target Price
★ $31.50
$16.17
AVG Volume (30 Days)
★ 998.8K
498.5K
Earning Date
11-05-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 48.04
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.30
P/E Ratio
★ N/A
$10.11
Revenue Growth
N/A
N/A
52 Week Low
$6.39
$12.72
52 Week High
$26.95
$16.67

Technical Indicators

Market Signals
Indicator
CRVS
INMD
Relative Strength Index (RSI) 50.34 38.94
Support Level $9.21 $13.27
Resistance Level $10.81 $13.98
Average True Range (ATR) 0.64 0.35
MACD 0.12 -0.01
Stochastic Oscillator 73.19 16.79

Price Performance

Historical Comparison
CRVS
INMD

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

About INMD InMode Ltd.

InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.

Share on Social Networks: